143 related articles for article (PubMed ID: 17924645)
1. Multiobjective long-term planning of biopharmaceutical manufacturing facilities.
Lakhdar K; Savery J; Papageorgiou LG; Farid SS
Biotechnol Prog; 2007; 23(6):1383-93. PubMed ID: 17924645
[TBL] [Abstract][Full Text] [Related]
2. Medium term planning of biopharmaceutical manufacture using mathematical programming.
Lakhdar K; Zhou Y; Savery J; Titchener-Hooker NJ; Papageorgiou LG
Biotechnol Prog; 2005; 21(5):1478-89. PubMed ID: 16209554
[TBL] [Abstract][Full Text] [Related]
3. Medium term planning of biopharmaceutical manufacture with uncertain fermentation titers.
Lakhdar K; Farid SS; Titchener-Hooker NJ; Papageorgiou LG
Biotechnol Prog; 2006; 22(6):1630-6. PubMed ID: 17137311
[TBL] [Abstract][Full Text] [Related]
4. Capacity planning for batch and perfusion bioprocesses across multiple biopharmaceutical facilities.
Siganporia CC; Ghosh S; Daszkowski T; Papageorgiou LG; Farid SS
Biotechnol Prog; 2014; 30(3):594-606. PubMed ID: 24376262
[TBL] [Abstract][Full Text] [Related]
5. Inexact fuzzy-stochastic mixed integer programming approach for long-term planning of waste management---Part B: case study.
Guo P; Huang GH
J Environ Manage; 2009; 91(2):441-60. PubMed ID: 19818549
[TBL] [Abstract][Full Text] [Related]
6. Throughput Optimization of Continuous Biopharmaceutical Manufacturing Facilities.
Garcia FA; Vandiver MW
PDA J Pharm Sci Technol; 2017; 71(3):189-205. PubMed ID: 27974629
[TBL] [Abstract][Full Text] [Related]
7. Application of a decision-support tool to assess pooling strategies in perfusion culture processes under uncertainty.
Lim AC; Zhou Y; Washbrook J; Sinclair A; Fish B; Francis R; Titchener-Hooker NJ; Farid SS
Biotechnol Prog; 2005; 21(4):1231-42. PubMed ID: 16080707
[TBL] [Abstract][Full Text] [Related]
8. Building biomanufacturing capacity--the chapter and verse.
Kamarck ME
Nat Biotechnol; 2006 May; 24(5):503-5. PubMed ID: 16680126
[TBL] [Abstract][Full Text] [Related]
9. Trends in capacity utilization for therapeutic monoclonal antibody production.
Langer ES
MAbs; 2009; 1(2):151-6. PubMed ID: 20061821
[TBL] [Abstract][Full Text] [Related]
10. An integrated two-stage optimization model for the development of long-term waste-management strategies.
Li YP; Huang GH; Yang ZF; Nie SL
Sci Total Environ; 2008 Mar; 392(2-3):175-86. PubMed ID: 18201748
[TBL] [Abstract][Full Text] [Related]
11. A software tool to assist business-process decision-making in the biopharmaceutical industry.
Mustafa MA; Washbrook J; Lim AC; Zhou Y; Titchener-Hooker NJ; Morton P; Berezenko S; Farid SS
Biotechnol Prog; 2004; 20(4):1096-102. PubMed ID: 15296435
[TBL] [Abstract][Full Text] [Related]
12. Strategic biopharmaceutical portfolio development: an analysis of constraint-induced implications.
George ED; Farid SS
Biotechnol Prog; 2008; 24(3):698-713. PubMed ID: 18426243
[TBL] [Abstract][Full Text] [Related]
13. How many patents does a biopharmaceutical company need?
Parida DK; Mehdiratta R; Saberwal G
Nat Biotechnol; 2008 Jul; 26(7):763-6. PubMed ID: 18612295
[TBL] [Abstract][Full Text] [Related]
14. A decision-support model for evaluating changes in biopharmaceutical manufacturing processes.
Chhatre S; Francis R; O'Donovan K; Titchener-Hooker NJ; Newcombe AR; Keshavarz-Moore E
Bioprocess Biosyst Eng; 2007 Jan; 30(1):1-11. PubMed ID: 17093973
[TBL] [Abstract][Full Text] [Related]
15. A tool for modeling strategic decisions in cell culture manufacturing.
Farid SS; Novais JL; Karri S; Washbrook J; Titchener-Hooker NJ
Biotechnol Prog; 2000; 16(5):829-36. PubMed ID: 11027178
[TBL] [Abstract][Full Text] [Related]
16. Identifying optimal regional solid waste management strategies through an inexact integer programming model containing infinite objectives and constraints.
He L; Huang GH; Zeng GM; Lu HW
Waste Manag; 2009 Jan; 29(1):21-31. PubMed ID: 18406594
[TBL] [Abstract][Full Text] [Related]
17. Stop making plans; start making decisions.
Mankins MC; Steele R
Harv Bus Rev; 2006 Jan; 84(1):76-84, 133. PubMed ID: 16447371
[TBL] [Abstract][Full Text] [Related]
18. Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry.
Stone JA; Banfield C; Pfister M; Tannenbaum S; Allerheiligen S; Wetherington JD; Krishna R; Grasela DM
J Clin Pharmacol; 2010 Sep; 50(9 Suppl):20S-30S. PubMed ID: 20881214
[TBL] [Abstract][Full Text] [Related]
19. Strategic groups in the biopharmaceutical industry: implications for performance.
Erden Z; von Krogh G; Nytorp C; Hultberg M
Drug Discov Today; 2009 Aug; 14(15-16):726-30. PubMed ID: 19416760
[TBL] [Abstract][Full Text] [Related]
20. The state of biopharmaceutical manufacturing.
Molowa DT; Mazanet R
Biotechnol Annu Rev; 2003; 9():285-302. PubMed ID: 14650933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
